Relmada Therapeutics
RLMD
44 hedge funds and large institutions have $1.68M invested in Relmada Therapeutics in 2025 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 14 reducing their positions, and 12 closing their positions.
7.22% less ownership
Funds ownership: 27.84% → 20.61% (-7.2%)
8% less funds holding
Funds holding: 48 → 44 (-4)
33% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 12
62% less capital invested
Capital invested by funds: $4.36M → $1.68M (-$2.68M)
71% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 14
Top Buyers
| 1 |
Goldman Sachs
New York
|
+$40.1K |
| 2 |
Two Sigma Advisers
New York
|
+$29.5K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$22K |
| 4 |
HF
HRT Financial
New York
|
+$17.3K |
| 5 |
Two Sigma Investments
New York
|
+$14.2K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Fidelity Investments
Boston,
Massachusetts
| – | -$15.6K | -30,062 | Closed |
|
52
Dimensional Fund Advisors
Austin,
Texas
| – | -$7.5K | -14,428 | Closed |
|
|
SIG
53
Sargent Investment Group
Bethesda,
Maryland
| – | -$4.71K | -11,670 | Closed |
|
|
BCM
54
Beaumont Capital Management
Boston,
Massachusetts
| – | -$5.72K | -11,006 | Closed |
|
|
TRCT
55
Tower Research Capital (TRC)
New York
| – | -$396 | -760 | Closed |
|
56
Wells Fargo
San Francisco,
California
| – | -$104 | -200 | Closed |
|
RLMD Hedge Fund Activity: Q1 2025 in Review
44 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2025, worth a combined $1.68M — down 62% from $4.36M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of RLMD and 8 opened new positions — a net loss of 4 holders — while 14 trimmed existing stakes and 4 added.
The largest buyer was Goldman Sachs, opening a new position worth an estimated $40.1K. The largest seller was Franklin Resources, cutting an estimated $417K.
- 44 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2025, down from 48 in Q4 2024.
- Funds reported $1.68M of Relmada Therapeutics stock for Q1 2025, down 62% quarter-over-quarter.
- 8 funds opened new Relmada Therapeutics positions in Q1 2025 and 12 closed out, a net change of -4 holders.
- The largest Relmada Therapeutics buyer in Q1 2025 was Goldman Sachs, an estimated $40.1K added.
- The largest Relmada Therapeutics seller in Q1 2025 was Franklin Resources, an estimated $417K sold.
Based on aggregated 13F filings for Q1 2025.